fluconazole has been researched along with Myelodysplastic Syndromes in 24 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival." | 9.12 | Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. ( Angulo-Gonzalez, D; Cornely, OA; Goh, YT; Hardalo, C; Helfgott, D; Holowiecki, J; Maertens, J; Perfect, J; Petrini, M; Stockelberg, D; Suresh, R; Ullmann, AJ; Walsh, TJ; Winston, DJ, 2007) |
| "We performed a randomized, controlled study comparing the prophylactic effects of capsule forms of fluconazole (n = 110) and itraconazole (n = 108) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy." | 9.12 | The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study. ( Aoyama, Y; Ito, Y; Kanamaru, A; Kiguchi, T; Masaoka, T; Matsuda, M; Matsuura, Y; Mugitani, A; Ohyashiki, K; Sakamoto, E; Takeuchi, M; Tamura, K; Urabe, A; Wakita, H; Yoshida, I, 2007) |
| "Posaconazole is superior to fluconazole (FLU) and itraconazole (ITRA) in the prevention of invasive fungal diseases (IFDs) in neutropenic patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 7.85 | Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. ( Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J, 2017) |
| "Posaconazole prophylaxis during induction chemotherapy for acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) has been shown to significantly decrease the incidence of invasive fungal disease (IFD) and increase overall survival in a trial setting, but only small real-life studies have been published." | 7.83 | Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes. ( Björkholm, M; Blennow, O; Cederlund, K; Dahlén, T; Kalin, M; Ljungman, P; Nordlander, A, 2016) |
| "Posaconazole is superior to fluconazole/itraconazole in preventing invasive fungal diseases (IFDs) in neutropenic patients." | 7.83 | Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital. ( Chan, TS; Gill, H; Hwang, YY; Kwong, YL; Marcella, SW, 2016) |
| "Fungal infections are a major cause of morbidity and mortality in patients undergoing induction chemotherapy for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 6.71 | Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. ( Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Koller, C; Kontoyiannis, D; Mattiuzzi, GN; Munsell, M; Raad, I; Shen, Y, 2003) |
| "The objective of this study was to assess the costs and effectiveness (avoided invasive fungal infections - IFIs; overall mortality) of prophylaxis with posaconazole 200 mg per os TID and standard azoles (fluconazole 400 mg per os OD, itraconazole 200 mg per os BID) in neutropenic patients with acute myelogenous leukaemia or myelodysplastic syndromes." | 5.14 | [Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome]. ( Lazzaro, C, 2010) |
| "In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival." | 5.12 | Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. ( Angulo-Gonzalez, D; Cornely, OA; Goh, YT; Hardalo, C; Helfgott, D; Holowiecki, J; Maertens, J; Perfect, J; Petrini, M; Stockelberg, D; Suresh, R; Ullmann, AJ; Walsh, TJ; Winston, DJ, 2007) |
| "We performed a randomized, controlled study comparing the prophylactic effects of capsule forms of fluconazole (n = 110) and itraconazole (n = 108) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy." | 5.12 | The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study. ( Aoyama, Y; Ito, Y; Kanamaru, A; Kiguchi, T; Masaoka, T; Matsuda, M; Matsuura, Y; Mugitani, A; Ohyashiki, K; Sakamoto, E; Takeuchi, M; Tamura, K; Urabe, A; Wakita, H; Yoshida, I, 2007) |
| "Posaconazole is superior to fluconazole (FLU) and itraconazole (ITRA) in the prevention of invasive fungal diseases (IFDs) in neutropenic patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 3.85 | Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. ( Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J, 2017) |
| "Posaconazole prophylaxis during induction chemotherapy for acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) has been shown to significantly decrease the incidence of invasive fungal disease (IFD) and increase overall survival in a trial setting, but only small real-life studies have been published." | 3.83 | Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes. ( Björkholm, M; Blennow, O; Cederlund, K; Dahlén, T; Kalin, M; Ljungman, P; Nordlander, A, 2016) |
| "Posaconazole is superior to fluconazole/itraconazole in preventing invasive fungal diseases (IFDs) in neutropenic patients." | 3.83 | Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital. ( Chan, TS; Gill, H; Hwang, YY; Kwong, YL; Marcella, SW, 2016) |
| "In patients undergoing induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), posaconazole has been proven more effective in the prevention of invasive fungal infection (IFI) than fluconazole or itraconazole (standard azoles) The current analysis seeks to estimate the cost effectiveness of prophylactic posaconazole compared with standard azoles in AML or MDS patients with severe chemotherapy-induced neutropenia in Sweden." | 3.80 | Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden. ( Åkerborg, Ö; Björkholm, M; Höglund, M; Lundberg, J, 2014) |
| "Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically." | 3.30 | Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer. ( Ameye, L; Aoun, M; Barnes, R; Baron, F; Bertz, H; Blijlevens, N; Bochud, PY; Chantepie, S; Cheung, KJ; Coiteux, V; Cordonnier, C; Donnelly, JP; Drgona, L; Heinz, WJ; Hepler, DA; Lamoth, F; Llorente, CC; Lodewyck, T; Loeffler, J; Maertens, J; Marchetti, O; Meert, L; Paesmans, M; Ráčil, Z; Robin, C; Schaefer-Prokop, C; Schwarzinger, M; Selleslag, D; Turlure, P; Vandercam, B; Verweij, P, 2023) |
| "Fungal infections are a major cause of morbidity and mortality in patients undergoing induction chemotherapy for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 2.71 | Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. ( Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Koller, C; Kontoyiannis, D; Mattiuzzi, GN; Munsell, M; Raad, I; Shen, Y, 2003) |
| "Posaconazole was introduced as the primary antifungal prophylaxis (PAP) in acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) patients during remission induction chemotherapy." | 1.42 | Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. ( Cho, SY; Choi, JH; Choi, JK; Choi, SM; Kim, HJ; Kim, SH; Kim, YJ; Lee, DG; Lee, HJ; Min, WS; Park, SH; Yoo, JH, 2015) |
| "Post-induction aplasia for acute myeloid leukemia/myelodysplastic syndrome is a high-risk period for invasive fungal diseases." | 1.38 | Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. ( Ananda-Rajah, MR; Bajel, A; Cheng, A; Downey, MT; Grigg, A; Slavin, MA; Spelman, T; Thursky, KT; Vincent, J, 2012) |
| "Posaconazole was associated with an overall cost savings (range = $Can1,765 to $Can4,505) in all of the scenarios evaluated." | 1.37 | Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. ( Dranitsaris, G; Khoury, H, 2011) |
| " No significant adverse reactions nor abnormality in clinical laboratory tests related with the dosing of fluconazole were observed in any of the patients." | 1.28 | [A clinical evaluation of injectable fluconazole in the treatment of deep mycosis associated with hematological malignancy]. ( Hojo, H; Lin, KY; Torii, Y; Toyama, K; Tsuda, A; Yoshikawa, O, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Maertens, J | 2 |
| Lodewyck, T | 1 |
| Donnelly, JP | 1 |
| Chantepie, S | 1 |
| Robin, C | 1 |
| Blijlevens, N | 1 |
| Turlure, P | 1 |
| Selleslag, D | 1 |
| Baron, F | 1 |
| Aoun, M | 1 |
| Heinz, WJ | 1 |
| Bertz, H | 1 |
| Ráčil, Z | 1 |
| Vandercam, B | 1 |
| Drgona, L | 1 |
| Coiteux, V | 1 |
| Llorente, CC | 1 |
| Schaefer-Prokop, C | 1 |
| Paesmans, M | 1 |
| Ameye, L | 1 |
| Meert, L | 1 |
| Cheung, KJ | 1 |
| Hepler, DA | 1 |
| Loeffler, J | 1 |
| Barnes, R | 1 |
| Marchetti, O | 1 |
| Verweij, P | 1 |
| Lamoth, F | 1 |
| Bochud, PY | 1 |
| Schwarzinger, M | 1 |
| Cordonnier, C | 1 |
| Cámara, R | 1 |
| Gozalbo, I | 1 |
| Jurado, M | 1 |
| Sanz, J | 1 |
| Aragón, B | 1 |
| Grau, S | 1 |
| Lundberg, J | 1 |
| Höglund, M | 1 |
| Björkholm, M | 2 |
| Åkerborg, Ö | 1 |
| Brissot, E | 1 |
| Cahu, X | 1 |
| Guillaume, T | 1 |
| Delaunay, J | 1 |
| Ayari, S | 1 |
| Peterlin, P | 1 |
| Le Bourgeois, A | 1 |
| Harousseau, JL | 1 |
| Milpied, N | 1 |
| Bene, MC | 1 |
| Moreau, P | 1 |
| Mohty, M | 1 |
| Chevallier, P | 1 |
| Dahlén, T | 1 |
| Kalin, M | 1 |
| Cederlund, K | 1 |
| Nordlander, A | 1 |
| Ljungman, P | 1 |
| Blennow, O | 1 |
| Cho, SY | 1 |
| Lee, DG | 1 |
| Choi, SM | 1 |
| Choi, JK | 1 |
| Lee, HJ | 1 |
| Kim, SH | 1 |
| Park, SH | 1 |
| Choi, JH | 1 |
| Yoo, JH | 1 |
| Kim, YJ | 1 |
| Kim, HJ | 1 |
| Min, WS | 1 |
| Chan, TS | 1 |
| Marcella, SW | 1 |
| Gill, H | 1 |
| Hwang, YY | 1 |
| Kwong, YL | 1 |
| Heidenreich, D | 1 |
| Kreil, S | 1 |
| Nolte, F | 1 |
| Reinwald, M | 1 |
| Hofmann, WK | 1 |
| Klein, SA | 1 |
| Karthaus, M | 1 |
| Stam, WB | 1 |
| O'Sullivan, AK | 1 |
| Rijnders, B | 1 |
| Lugtenburg, E | 1 |
| Span, LF | 1 |
| Janssen, JJ | 1 |
| Jansen, JP | 1 |
| Lazzaro, C | 1 |
| Dranitsaris, G | 1 |
| Khoury, H | 1 |
| Inoue, Y | 1 |
| Onoda, M | 1 |
| Aihara, M | 1 |
| Koiwa, K | 1 |
| Yamane, Y | 1 |
| Ikezawa, Z | 1 |
| Vuichard, D | 1 |
| Conen, A | 1 |
| Brenner, M | 1 |
| Itin, P | 1 |
| Flückiger, U | 1 |
| Ananda-Rajah, MR | 1 |
| Grigg, A | 1 |
| Downey, MT | 1 |
| Bajel, A | 1 |
| Spelman, T | 1 |
| Cheng, A | 1 |
| Thursky, KT | 1 |
| Vincent, J | 1 |
| Slavin, MA | 1 |
| Mattiuzzi, GN | 1 |
| Estey, E | 1 |
| Raad, I | 1 |
| Giles, F | 1 |
| Cortes, J | 1 |
| Shen, Y | 1 |
| Kontoyiannis, D | 1 |
| Koller, C | 1 |
| Munsell, M | 1 |
| Beran, M | 1 |
| Kantarjian, H | 1 |
| Tsutsumi, Y | 1 |
| Ehira, N | 1 |
| Kanamori, H | 1 |
| Yamato, H | 1 |
| Obara, S | 1 |
| Tanaka, J | 1 |
| Asaka, M | 1 |
| Imamura, M | 1 |
| Masauzi, N | 1 |
| Schriber, J | 1 |
| Almond, H | 1 |
| Alvarnas, J | 1 |
| Sarkadee-Adoo, C | 1 |
| Nakagawa, Y | 1 |
| Cornely, OA | 1 |
| Winston, DJ | 1 |
| Perfect, J | 1 |
| Ullmann, AJ | 2 |
| Walsh, TJ | 1 |
| Helfgott, D | 1 |
| Holowiecki, J | 1 |
| Stockelberg, D | 1 |
| Goh, YT | 1 |
| Petrini, M | 1 |
| Hardalo, C | 1 |
| Suresh, R | 1 |
| Angulo-Gonzalez, D | 1 |
| Ito, Y | 1 |
| Ohyashiki, K | 1 |
| Yoshida, I | 1 |
| Takeuchi, M | 1 |
| Aoyama, Y | 1 |
| Mugitani, A | 1 |
| Matsuura, Y | 1 |
| Wakita, H | 1 |
| Matsuda, M | 1 |
| Sakamoto, E | 1 |
| Kiguchi, T | 1 |
| Urabe, A | 1 |
| Tamura, K | 1 |
| Kanamaru, A | 1 |
| Masaoka, T | 1 |
| van Nieuwkoop, C | 1 |
| van Dissel, JT | 1 |
| Gonzalez, AV | 1 |
| Almyroudis, NG | 1 |
| Segal, BH | 1 |
| Toyama, K | 1 |
| Lin, KY | 1 |
| Hojo, H | 1 |
| Tsuda, A | 1 |
| Torii, Y | 1 |
| Yoshikawa, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia[NCT01615809] | Phase 2 | 32 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients[NCT00044486] | Phase 3 | 602 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Revision of Antifungal Strategies Definitions for Invasive Fungal Infections (Proven/Probable/Possible) in Patients With Hematological Malignancies (REDEFI-SEIFEM)[NCT04024995] | 513 participants (Actual) | Observational [Patient Registry] | 2019-09-01 | Completed | |||
| Invasive Fungal Infections in Patients Following Stem Cell Transplant[NCT04619147] | 300 participants (Anticipated) | Observational | 2021-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence of invasive pulmonary aspergillosis during the Abelcet® prophylactic treatment period was assessed by the relation between the number of patients with invasive pulmonary aspergillosis and the number of paediatric patients on prophylaxis with Acute Leukaemia (AL) undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 3 |
Percentage of deaths related to Invasive Pulmonary Aspergillosis during the prophylactic treatment period with Abelcet® in paediatric patients with Acute Leukaemia undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | percentage of deaths (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
is assessed by the proportion of patients who discontinue prophylactic treatment with Abelcet® due to an adverse event that is related or not to the study drug or for intolerability to it. The last week of treatment will have a different calendar for each participant, depending on the number of cicles needed by each patient (it has been anticipated up to 5 cicles of 2-6 weeks each). (NCT01615809)
Timeframe: at the Baseline visit (week 1) and during the Last week of treatment, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
1 review available for fluconazole and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point.
Topics: Antifungal Agents; Fluconazole; Humans; Immunocompromised Host; Itraconazole; Mycoses; Myelodysplast | 2008 |
5 trials available for fluconazole and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
Topics: Antifungal Agents; Caspofungin; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Leukem | 2023 |
[Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].
Topics: Administration, Oral; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Drug Thera | 2003 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Capsules; Female; Fluconazole; Humans; Itraconazole; Jap | 2007 |
18 other studies available for fluconazole and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.
Topics: Adult; Aged; Antifungal Agents; Cost-Benefit Analysis; Female; Fluconazole; Humans; Invasive Fungal | 2017 |
Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III | 2014 |
Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.
Topics: Acute Disease; Adult; Aged; Chemoprevention; Female; Fluconazole; Humans; Leukemia; Male; Middle Age | 2015 |
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; C | 2016 |
Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
Topics: Adult; Antifungal Agents; Female; Fluconazole; Humans; Incidence; Induction Chemotherapy; Leukemia, | 2015 |
Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital.
Topics: Antifungal Agents; Cost-Benefit Analysis; Decision Support Techniques; Fluconazole; Hong Kong; Hospi | 2016 |
Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis.
Topics: Adult; Aged; Female; Fluconazole; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; | 2016 |
Treatment of aspergillosis.
Topics: Antifungal Agents; Aspergillosis; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Myelo | 2008 |
Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Topics: Adult; Aged; Antifungal Agents; Costs and Cost Analysis; Female; Fluconazole; Humans; Itraconazole; | 2008 |
Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.
Topics: Antifungal Agents; Antineoplastic Agents; Canada; Cost Savings; Cost-Benefit Analysis; Decision Supp | 2011 |
Cryptococcal cellulitis in a patient with myelodysplastic syndrome.
Topics: Aged, 80 and over; Antifungal Agents; Cellulitis; Cryptococcosis; Cryptococcus neoformans; Debrideme | 2011 |
Bullous cellulitis with Cryptococcus neoformans.
Topics: Aged; Antifungal Agents; Biopsy; Cellulitis; Cryptococcosis; Cryptococcus neoformans; Debridement; F | 2011 |
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antifungal Agents; Female; Fluco | 2012 |
Pancreatitis complications in a patient with myelodysplastic syndrome, who was treated with fluconazole.
Topics: Aged; Antifungal Agents; Fluconazole; Humans; Male; Myelodysplastic Syndromes; Pancreatitis | 2004 |
Successful allogeneic bone marrow transplantation in a patient with active Coccidioidomycosis.
Topics: Adult; Amphotericin B; Antifungal Agents; Bone Marrow Transplantation; Coccidioidomycosis; Female; F | 2005 |
[Prophylactic administration of fluconazole and itraconazole in febrile neutropenia associated with hematopoietic malignancy].
Topics: Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic | 2006 |
Posaconazole prophylaxis in hematologic cancer.
Topics: Antifungal Agents; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Mycoses; Myelodyspla | 2007 |
[A clinical evaluation of injectable fluconazole in the treatment of deep mycosis associated with hematological malignancy].
Topics: Acute Disease; Adolescent; Adult; Aged; Antifungal Agents; Candida; Candidiasis; Drug Evaluation; Dr | 1989 |